Latest news

Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 – A potent, first-in-class antiviral…

Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent…

Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma

Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of…

Debiopharm Group invests in Searchbox SA, a semantic search engine for professionals

The Japanese Cancer Association and Debiopharm Group present the JCA-Mauvernay Award to Dr Ushijima for his oncology research

BioAlps annonce le lauréat de son prix : la famille Mauvernay, fondatrice de Debiopharm, une famille d’entrepreneurs au service de…

Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC25 inhibitor…

The Debiopharm Life Sciences Award goes to Dr Lluis Quintana-Murci for his novel and original research on the human evolutionary…